IO Biotech Business Summary

IO Biotech, Inc. (IOBT) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, research collaborations, and future milestone-based payments or royalties from its proprietary T-win technology platform. The company’s business model is centered on the development of off-the-shelf, immune-modulating cancer vaccines designed to disrupt immunosuppressive pathways in the tumor microenvironment. Its primary business segments are focused on oncology, with its lead candidate, Cylembio (IO102-IO103), targeting IDO and PD-L1 in combination with checkpoint inhibitors for advanced melanoma and other solid tumors. IO Biotech competes directly with other immunotherapy and cancer vaccine developers such as Citius Oncology, Artiva Biotherapeutics, and Anixa Biosciences. As of early 2026, the company occupies a high-risk, micro-cap niche in the market, currently undergoing a strategic review of alternatives to secure the capital necessary for its next phase of registrational trials. The company was founded by a distinguished group of scientists and industry veterans, including Dr. Mai-Britt Zocca, Dr. Mads Hald Andersen, and Dr. Inge Marie Svane, who pioneered the T-win platform at the Center for Cancer Immune Therapy in Denmark. The current leadership team is headed by Founder and CEO Dr. Mai-Britt Zocca, who brings over 25 years of experience in biotech management, supported by Chief Technical Officer Eric Faulkner, Chief Financial Officer Amy Sullivan, and Chief Medical Officer Dr. Qasim Ahmad. The company’s board is chaired by Dr. Peter Hirth, the former CEO of Plexxikon, and includes representatives from prominent life science investors. Notable institutional backing has historically come from Lundbeckfonden BioCapital, Sunstone Life Science Ventures, and Vivo Capital, reflecting a strong pedigree of European and American venture support despite the company's current focus on strategic restructuring.